Spiriva campaign gets All-Star debut

Share this article:
Spiriva campaign gets All-Star debut
Spiriva campaign gets All-Star debut
Major League Baseball's annual All-Star Game last night featured new DTC spots for Spiriva HandiHaler, an inhaler indicated for chronic bronchitis and emphysema.

The television spots were created by Ogilvy Healthworld, according to a Boehringer Ingelheim spokesperson, with forthcoming digital work handled by Digitas Health. Boehringer was not able to comment on the digital component prior to launch. The media mix for the campaign is currently limited to television, according to the spokesperson.

60-second version of the spot on Spiriva's brand.com site features an upper middle-aged female actor speaking about chronic obstructive pulmonary disease (COPD): “It can be tough living with COPD, but I try not to let it slow me down.” The actor goes on to describe respiratory-intensive activities – swimming, dancing and playing hide and seek – that she enjoys, indicating that Spiriva has helped facilitate participation in those activities: “I'm breathing better with Spiriva.”

The All-Star Game aired on the FOX Network at 8pm, and included a guest appearance from President Obama, who threw the first pitch of the game and also joined announcers Joe Buck and Tim McCarver in the box. National audience numbers were not yet available from Nielsen, though preliminary data from 56 markets showed a 10.4 household rating. The National League lost the game for the thirteenth consecutive year. A Flomax billboard was almost constantly visible behind home plate.

Spiriva is distributed by Boehringer Ingelheim (BI) and marketed by BI and Pfizer in the US. Marketing duties are shared "50/50" between the two companies, according to a BI spokesperson. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...